Media Center
Latest
Results
Latest
Latest press releases
-
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
-
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
-
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
-
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
-
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
Contact the US media team
The telephone number below is for journalists or people with media related questions only. General or marketing inquiries will not be answered.
US Media Line: 1-302-885-2677
Email: USMediaTeam@astrazeneca.com
For all non-media related questions, please visit the contact us page or call 1-800-236-9933.
Please note:
It is against AstraZeneca policy to provide a list of our vendors to members of the media.
These press releases were issued in the United States (US) and are posted here as reference information for US investors and journalists only. The information contained in each press release was accurate at the time of issuance, and AstraZeneca assumes no responsibility for updating the information to reflect subsequent developments.
View information on AstraZeneca products, including their current US Prescribing Information.
Investor Relations
View investor information, financial results, annual reports, and other useful information for shareholders on our global site.